PTC Therapeutics Announces Initiation of Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia

Third trial initiated in 2020 from compounds identified from PTC's Bio-e platform SOUTH PLAINFIELD, N.J., Nov. 30, 2020 -- (Healthcare Sales & Marketing Network) -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the initiation of the registrati... Biopharmaceuticals PTC Therapeutics, vatiquinone, Friedreich ataxia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news